Active Psychology & Behaviour Mental Health

Certain about uncertainty: bridging cells and the clinic to uncover causal mechanisms of anxiety interventions

In plain English

AI plain-English summary

When someone with anxiety faces an uncertain situation, their brain may treat every unknown as a potential threat—and this project aims to pinpoint exactly how two different treatments fix that broken calculation. Intolerance of uncertainty is a core driver of anxiety disorders, yet it remains unclear why both medication and psychological therapy can reduce it. The researchers propose that serotonin and noradrenaline—the neurotransmitters targeted by anti-anxiety drugs—and the cognitive techniques used in therapy (such as reinterpreting a threat) converge on the same underlying mechanism: altered uncertainty processing. Current treatments are prescribed largely by trial and error, with no way to predict which will work for a given person. The team will build computational models that capture each individual’s “uncertainty fingerprint”—a measure of how they process different types of uncertainty across different cognitive tasks. By tracing this fingerprint from brain cells and circuits in animals to clinical responses in humans, they aim to reveal the causal chain linking treatment to symptom relief. If successful, this could shift anxiety care from one-size-fits-all prescribing to precision medicine, where a person’s unique uncertainty fingerprint determines whether they receive medication, therapy, or both.

View original technical description
In an uncertain situation, people rely on clues from the environment – things known to be predictable from past experience – to determine what will happen next. If someone cannot predict what will happen next, anything could seem like a threat. Intolerance of uncertainty is increasingly recognised as a key risk factor in a range of mental health difficulties, most notably anxiety disorders. Research suggests that two neurotransmitters targeted by anti-anxiety medication, serotonin and noradrenaline, are crucially involved in how the brain represents uncertainty. Furthermore, psychological therapies incorporate various techniques (e.g., reinterpretation) targeting the belief that uncertainty is threatening. We propose that these two effective interventions act via a common core causal mechanism: altered uncertainty processing. To address this, we will use computational models that can capture an individual's ‘uncertainty fingerprint’ – a measure of how people process different kinds of uncertainty in different cognitive contexts. By working across scales and species, we will reveal how anxiety medications and psychological therapy improve symptoms via changes in how the brain encodes uncertainty, moving from cells and circuits to clinical treatment. This primes the field for the development of precision medicine approaches in anxiety, tailoring treatments according to each person's 'uncertainty fingerprint'.

View the original record at the funder ↗

Researchers

Anna Bevan (EPMC Awardee)Christoph Mathys (EPMC Awardee)Stephanie Archer (EPMC Awardee)Tim Dalgleish (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Discovering therapeutic mechanisms and predicting psychological treatment outcome: towards stratified interventions for anxiety
MICA: The Translational, Computational and Neurocognitive Basis of Anxiety
Disentangling the cognitive mechanisms of different anxiety disorders
Investigating the mechanisms of acceptance-based therapy components on avoidance in individuals with anxiety disorders
ANXIOMICS: Finding the mind, brain and immune pathways to anxiety

Original classification

Directed Call - full

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.